Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Neuilly-Sur-Seine – page 116

3 430 clinical trials in Neuilly-Sur-Seine, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Neuilly-Sur-Seine at a glance
3 430
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 430 trials in Neuilly-Sur-Seine

Open in trial search

Study of Daily Oral Ibutamoren Mesilate in Treatment‑Naïve Prepubertal Children with Growth Hormone Deficiency

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Ibutamoren Mesilate
  • Sponsor:Lumos Pharma LLC

Avian influenza

Not yet recruiting

Immunogenicity and safety of intradermal zoonotic influenza vaccine (H5N8) compared with intramuscular administration in adults 40–80 years with avian influenza

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:INFLUENZA A/ASTRAKHAN/3212/2020 (H5N8)-LIKE STRAIN (CBER-RG8A) (CLADE 2.3.4.4B)
  • Sponsor:University Of Antwerp

Neoplasm malignant

Not yet recruiting

Phase 1/2 study of AVZO-023 drug combination in patients with advanced cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Avenzo Therapeutics Inc.

Multifocal motor neuropathy

Not yet recruiting

Phase 1b study of empasiprubart in adults with multifocal motor neuropathy to assess nerve morphology by ultrasound

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

HIV infection

Not yet recruiting

Study of Baricitinib and Sirolimus to Maintain HIV Infection Control After Antiretroviral Treatment Interruption in Adults

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Baricitinib
  • Sponsor:ANRS Maladies Infectieuses Emergentes

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

Hereditary ataxia+1

Not yet recruiting

Long‑term safety of intrathecal VO659 in participants with Huntington’s disease, spinocerebellar ataxia type 1 or type 3

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:VO659
  • Sponsor:Vico Therapeutics B.V.

Prostate cancer metastatic

Not yet recruiting

Study of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Acne

Not yet recruiting

Low-dose isotretinoin compared with drug combination for treating acne in adult women: a two‑step randomized trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Adapalene
  • Sponsor:Assistance Publique Hopitaux De Paris

Acute myeloid leukaemia

Not yet recruiting

Study of quizartinib‑based drug combination on measurable residual disease in adults 18‑60 with acute myeloid leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Azacitidine
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Hypersomnia

Not yet recruiting

Long‑term Safety and Tolerability Study of TAK‑360 in Adults with Narcolepsy or Idiopathic Hypersomnia

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Takeda Development Center Americas Inc.

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Neuilly-Sur-Seine

What the registry says about research in the country

01 Gastrointestinal Research

Extensive clinical trials focusing on inflammatory bowel diseases, particularly investigating innovative treatments for Crohn's Disease and Ulcerative Colitis. Multiple studies are evaluating novel therapeutic approaches for patients with moderate to severe conditions.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatments
  • Post-operative Care Studies

Research includes both induction and maintenance therapies, with emphasis on long-term patient outcomes.

02 Cardiovascular Studies

Innovative research in cardiac conditions, including studies on acute myocarditis treatment and prevention of post-operative complications. Trials are examining both therapeutic and preventive approaches.

  • Myocarditis Treatment
  • Post-operative Care
  • Cardiac Surgery Outcomes

Focus on improving patient outcomes through targeted interventions and innovative surgical techniques.

03 Oncology Research

Advanced studies in cancer treatment, including trials for head and neck squamous cell carcinoma and colorectal cancer. Research focuses on both targeted therapies and combination treatments.

  • Metastatic Cancer Treatment
  • Colorectal Cancer Management
  • Prostate Cancer Therapy

Emphasis on developing personalized treatment approaches and improving survival rates.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.